Your browser doesn't support javascript.
loading
Tripartite motif 38 alleviates the pathological process of NAFLD-NASH by promoting TAB2 degradation.
Yao, Xinxin; Dong, Ruixiang; Hu, Sha; Liu, Zhen; Cui, Jie; Hu, Fengjiao; Cheng, Xu; Wang, Xiaoming; Ma, Tengfei; Tian, Song; Zhang, Xiao-Jing; Hu, Yufeng; Bai, Lan; Li, Hongliang; Zhang, Peng.
Afiliação
  • Yao X; Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China; Institute of Model Animal, Wuhan University, Wuhan, China.
  • Dong R; Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China; Institute of Model Animal, Wuhan University, Wuhan, China.
  • Hu S; Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China; Institute of Model Animal, Wuhan University, Wuhan, China.
  • Liu Z; Institute of Model Animal, Wuhan University, Wuhan, China.
  • Cui J; Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China.
  • Hu F; Institute of Model Animal, Wuhan University, Wuhan, China; Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Cheng X; Gannan Innovation and Translational Medicine Research Institute, Ganzhou, China; Key Laboratory of Cardiovascular Disease Prevention and Control, Ministry of Education, First Affiliated Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, China.
  • Wang X; Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China; Institute of Model Animal, Wuhan University, Wuhan, China.
  • Ma T; Department of Neurology, Huanggang Central Hospital, Huanggang, China.
  • Tian S; Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China; Institute of Model Animal, Wuhan University, Wuhan, China.
  • Zhang XJ; Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China; Institute of Model Animal, Wuhan University, Wuhan, China.
  • Hu Y; Gannan Innovation and Translational Medicine Research Institute, Ganzhou, China; Key Laboratory of Cardiovascular Disease Prevention and Control, Ministry of Education, First Affiliated Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, China.
  • Bai L; Gannan Innovation and Translational Medicine Research Institute, Ganzhou, China; Key Laboratory of Cardiovascular Disease Prevention and Control, Ministry of Education, First Affiliated Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, China. Electronic address: bailan@gmu.e
  • Li H; Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China; Institute of Model Animal, Wuhan University, Wuhan, China; Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China; Gannan Innovation and Translational Medicine Research Institute,
  • Zhang P; Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China; Institute of Model Animal, Wuhan University, Wuhan, China. Electronic address: zhp@whu.edu.cn.
J Lipid Res ; 64(7): 100382, 2023 07.
Article em En | MEDLINE | ID: mdl-37116711
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: J Lipid Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: J Lipid Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China